Coave Therapeutics

Coave Therapeutics, founded in 2014 and headquartered in Paris, is a clinical-stage biotechnology firm focused on developing gene therapies for rare ocular and central nervous system (CNS) diseases. The company, formerly known as Horama, was established by Rodolphe Clerval. Clerval, who took on the CEO role in 2020, brings over two decades of experience in the pharmaceutical and biotech sectors, including co-founding Enterome and holding positions at Genzyme and TcLand Expression. His background in biochemical engineering and as a financial analyst has shaped his leadership in securing strategic partnerships and funding.

The company's business model is centered on the research, development, and eventual commercialization of advanced gene therapies. Revenue generation is anticipated through strategic partnerships with larger pharmaceutical companies, licensing agreements for its platform technology, and the successful clinical progression and market approval of its therapeutic candidates. Coave Therapeutics targets debilitating conditions with significant unmet medical needs, operating in the highly specialized market of genetic medicine. The company has secured significant funding to advance its work, raising a total of over $77 million across several rounds from a syndicate of international life sciences investors including Novo Holdings, Bpifrance, Seroba Life Sciences, and Fund+.

Coave's core asset is its proprietary ALIGATER™ (Advanced Vectors-Ligand Conjugates) platform. This technology aims to overcome critical limitations of current adeno-associated virus (AAV) vectors by chemically conjugating targeting ligands—such as small molecules or peptides—to the AAV capsid surface. This process enhances the targeted delivery of genetic payloads to specific tissues like the eye and CNS, improving transduction efficiency and safety while allowing for lower, safer doses. A key feature of the ALIGATER platform is that it avoids the need for prior AAV capsid modifications, which streamlines the manufacturing process. The company's pipeline includes preclinical programs for conditions such as Parkinson's disease, Gaucher Disease, and Stargardt's disease, with plans to advance candidates toward clinical trials.

Keywords: gene therapy, AAV vectors, neurodegenerative diseases, ocular diseases, CNS disorders, ALIGATER platform, targeted drug delivery, genetic medicine, biotechnology, retinal dystrophy, Stargardt's disease, Parkinson's disease, Gaucher Disease, AAV-Ligand Conjugates, clinical-stage, rare diseases, biopharmaceutical, venture capital, preclinical development, therapeutic candidates